Published in Neuroradiology on December 02, 2010
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol (2012) 1.42
Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods. Cancer Manag Res (2014) 1.35
Improving tumour heterogeneity MRI assessment with histograms. Br J Cancer (2014) 1.18
Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. J Clin Oncol (2015) 1.06
Functional imaging in adult and paediatric brain tumours. Nat Rev Clin Oncol (2012) 1.05
Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study. Neuro Oncol (2011) 1.02
The emerging role of diffusion-weighted MRI in prostate cancer management. Nat Rev Urol (2012) 0.99
Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response. Front Neurol (2015) 0.97
Early perfusion changes in patients with recurrent high-grade brain tumor treated with Bevacizumab: preliminary results by a quantitative evaluation. J Exp Clin Cancer Res (2012) 0.93
Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients. Neuro Oncol (2014) 0.88
Diffusion MRI and novel texture analysis in osteosarcoma xenotransplants predicts response to anti-checkpoint therapy. PLoS One (2013) 0.86
Early biomarkers from dynamic contrast-enhanced magnetic resonance imaging to predict the response to antiangiogenic therapy in high-grade gliomas. Neuroradiology (2015) 0.83
Subconjunctival bevacizumab for primary pterygium excision; a randomized clinical trial. J Ophthalmic Vis Res (2014) 0.83
Diffusion MRI in early cancer therapeutic response assessment. NMR Biomed (2016) 0.83
Evaluation of low-grade glioma structural changes after chemotherapy using DTI-based histogram analysis and functional diffusion maps. Eur Radiol (2015) 0.81
Histogram Analysis of Diffusion Weighted Imaging at 3T is Useful for Prediction of Lymphatic Metastatic Spread, Proliferative Activity, and Cellularity in Thyroid Cancer. Int J Mol Sci (2017) 0.80
Apparent diffusion coefficient histogram metrics correlate with survival in diffuse intrinsic pontine glioma: a report from the Pediatric Brain Tumor Consortium. Neuro Oncol (2015) 0.80
Diffusion tensor histogram analysis of pediatric diffuse intrinsic pontine glioma. Biomed Res Int (2014) 0.80
Weekly response assessment of involved lymph nodes to radiotherapy using diffusion-weighted MRI in oropharynx squamous cell carcinoma. Med Phys (2016) 0.79
Pre-Operative Perfusion Skewness and Kurtosis Are Potential Predictors of Progression-Free Survival after Partial Resection of Newly Diagnosed Glioblastoma. Korean J Radiol (2016) 0.79
Investigation of the diffusion abnormality index as a new imaging biomarker for early assessment of brain tumor response to radiation therapy. Neuro Oncol (2013) 0.78
Recombinant interleukin-1 receptor antagonist conjugated to superparamagnetic iron oxide nanoparticles for theranostic targeting of experimental glioblastoma. Neoplasia (2015) 0.78
Potential of MR histogram analyses for prediction of response to chemotherapy in patients with colorectal hepatic metastases. Eur Radiol (2015) 0.78
Apparent diffusion coefficient histogram shape analysis for monitoring early response in patients with advanced cervical cancers undergoing concurrent chemo-radiotherapy. Radiat Oncol (2016) 0.77
Correlation of (18)F-FDG PET and MR Apparent Diffusion Coefficient (ADC) Histogram Metrics with Survival in Diffuse Intrinsic Pontine Glioma: A Report from the Pediatric Brain Tumor Consortium. J Nucl Med (2017) 0.77
Potential of Diffusion Tensor Imaging and Relaxometry for the Detection of Specific Pathological Alterations in Parkinson's Disease (PD). PLoS One (2015) 0.76
MRI and thallium-201 SPECT in the prediction of survival in glioma. Neuroradiology (2011) 0.76
Alterations in fiber pathways reveal brain tumor typology: a diffusion tractography study. PeerJ (2014) 0.76
Diffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinoma. Br J Cancer (2013) 0.75
Vasculature-specific MRI reveals differential anti-angiogenic effects of a biomimetic peptide in an orthotopic breast cancer model. Angiogenesis (2014) 0.75
MRI in Glioma Immunotherapy: Evidence, Pitfalls, and Perspectives. J Immunol Res (2017) 0.75
Diffusion MRI phenotypes predict overall survival benefitfrom anti-VEGF monotherapy in recurrent glioblastoma:Converging evidence from phase II trials. Clin Cancer Res (2017) 0.75
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55
K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med (2008) 27.35
Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol (1990) 18.71
User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage (2006) 18.68
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol (2010) 14.79
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol (2007) 12.62
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell (2007) 12.52
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res (2007) 9.21
Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol (1999) 8.69
Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology (2008) 8.10
Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology (1988) 8.08
Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia (2009) 7.44
Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol (2006) 7.19
Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst (2000) 5.14
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol (2008) 4.39
Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia (2001) 4.22
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology (2006) 4.06
The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol (2006) 3.83
Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol (2010) 3.67
The role of diffusion-weighted imaging in patients with brain tumors. AJNR Am J Neuroradiol (2001) 3.58
Differentiation of clinically benign and malignant breast lesions using diffusion-weighted imaging. J Magn Reson Imaging (2002) 3.35
Response criteria for glioma. Nat Clin Pract Oncol (2008) 2.69
Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology (2009) 2.55
Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol (2007) 2.39
Technology insight: water diffusion MRI--a potential new biomarker of response to cancer therapy. Nat Clin Pract Oncol (2008) 2.03
Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology (2006) 1.95
Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging (2010) 1.82
Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst (2005) 1.76
Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer (2008) 1.65
Malignant renal neoplasms: correlation between ADC values and cellularity in diffusion weighted magnetic resonance imaging at 3 T. Radiol Med (2008) 1.58
Correlation of diffusion-weighted MR imaging with cellularity of renal tumours. Anticancer Res (2005) 1.46
Monitoring therapeutic responses of primary bone tumors by diffusion-weighted image: Initial results. Eur Radiol (2006) 1.45
Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. Clin Cancer Res (2004) 1.40
Relation between cancer cellularity and apparent diffusion coefficient values using diffusion-weighted magnetic resonance imaging in breast cancer. Radiat Med (2008) 1.36
Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus diffusion-weighted MR imaging. Radiology (2005) 1.35
Measurement of tumor "size" in recurrent malignant glioma: 1D, 2D, or 3D? AJNR Am J Neuroradiol (2005) 1.30
Dynamic imaging of emerging resistance during cancer therapy. Cancer Res (2006) 1.23
Imaging response criteria for recurrent gliomas treated with bevacizumab: role of diffusion weighted imaging as an imaging biomarker. J Neurooncol (2009) 1.21
Malignant supratentorial astrocytoma treated with postoperative radiation therapy: prognostic value of pretreatment quantitative diffusion-weighted MR imaging. Radiology (2007) 1.15
Repeatability of quantitative parameters derived from diffusion tensor imaging in patients with glioblastoma multiforme. J Magn Reson Imaging (2009) 1.05
The role of diffusion-weighted imaging in the differential diagnosis of intracranial cystic mass lesions: a report of 147 lesions. Surg Neurol (2006) 1.04
Advances in evaluation of primary brain tumors. Semin Nucl Med (2008) 0.92
Expensive cancer drugs with modest benefit ignite debate over solutions. J Natl Cancer Inst (2008) 0.83
Contribution of the apparent diffusion coefficient in perilesional edema for the assessment of brain tumors. J Neuroradiol (2008) 0.78
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer (2012) 3.66
The head nodding syndrome--clinical classification and possible causes. Epilepsia (2008) 2.74
The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol (2013) 2.65
Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme. Clin Cancer Res (2008) 2.22
DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res (2003) 2.14
Changes of renal blood flow after ESWL: assessment by ASL MR imaging, contrast enhanced MR imaging, and renal resistive index. Eur J Radiol (2009) 2.02
Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma. Neurology (2014) 2.02
Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. Cancer Res (2006) 1.99
Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet (2004) 1.80
DNA hypomethylation and ovarian cancer biology. Cancer Res (2004) 1.75
Appendicitis: should diagnostic imaging be performed if the clinical presentation is highly suggestive of the disease? Gastroenterology (2002) 1.68
Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res (2005) 1.62
Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease. Brain (2013) 1.54
Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests. Clin Chem Lab Med (2012) 1.53
HOXA11 DNA methylation--a novel prognostic biomarker in ovarian cancer. Int J Cancer (2008) 1.44
Similar qualitative and quantitative changes of mitochondrial respiration following strength and endurance training in normoxia and hypoxia in sedentary humans. Am J Physiol Regul Integr Comp Physiol (2011) 1.38
White and gray matter abnormalities in idiopathic rapid eye movement sleep behavior disorder: a diffusion-tensor imaging and voxel-based morphometry study. Ann Neurol (2010) 1.34
HER3 is a determinant for poor prognosis in melanoma. Clin Cancer Res (2008) 1.33
O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. J Nucl Med (2011) 1.30
Model-based imaging of cardiac electrical excitation in humans. IEEE Trans Med Imaging (2002) 1.30
[18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. Neuro Oncol (2013) 1.30
Epilepsy and neurocysticercosis in rural Tanzania-An imaging study. Epilepsia (2008) 1.26
Imaging early practice effects in arithmetic. Neuroimage (2007) 1.26
Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET. Eur J Nucl Med Mol Imaging (2014) 1.26
A widespread distinct pattern of cerebral atrophy in patients with alcohol addiction revealed by voxel-based morphometry. J Neurol Neurosurg Psychiatry (2006) 1.19
Sonographic findings in stress fractures of the lower limb: preliminary findings. Eur Radiol (2004) 1.18
Implementation of computer-based quality-of-life monitoring in brain tumor outpatients in routine clinical practice. J Pain Symptom Manage (2010) 1.15
Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis. PLoS One (2008) 1.14
Persistent median artery in the carpal tunnel: color Doppler ultrasonographic findings. J Ultrasound Med (2002) 1.11
Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. Brain (2005) 1.09
A developmental fMRI study of nonsymbolic numerical and spatial processing. Cortex (2007) 1.09
Pattern of brain atrophy in elderly patients with depression revealed by voxel-based morphometry. Psychiatry Res (2008) 1.08
Visualization of nigrosome 1 and its loss in PD: pathoanatomical correlation and in vivo 7T MRI. Neurology (2014) 1.07
DNA methylation in serum and tumors of cervical cancer patients. Clin Cancer Res (2004) 1.06
The iceman: discovery and imaging. Radiology (2003) 1.06
Expression of the E2F family of transcription factors and its clinical relevance in ovarian cancer. Ann N Y Acad Sci (2006) 1.06
Methylation status and expression of human telomerase reverse transcriptase in ovarian and cervical cancer. Gynecol Oncol (2004) 1.06
Progression of brain atrophy in multiple system atrophy. A longitudinal VBM study. J Neurol (2007) 1.04
An fMRI study of the numerical Stroop task in individuals with and without minimal cognitive impairment. Cortex (2008) 1.02
SFRP2 methylation in fecal DNA--a marker for colorectal polyps. Int J Colorectal Dis (2007) 1.02
Significance of MRI in diagnosis and differential diagnosis of Parkinson's disease. Neurodegener Dis (2010) 1.02
A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07). Neuro Oncol (2013) 1.01
Prognostic value at 5 years of microvascular obstruction after acute myocardial infarction assessed by cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2012) 1.00
Dialysis-related amyloidosis revisited. AJR Am J Roentgenol (2005) 1.00
Cyclin E dysregulation and chromosomal instability in endometrial cancer. Oncogene (2004) 0.99
Methylated DNA collected by tampons--a new tool to detect endometrial cancer. Cancer Epidemiol Biomarkers Prev (2004) 0.99
Analysis of methylated genes in peritoneal fluids of ovarian cancer patients: a new prognostic tool. Clin Chem (2004) 0.98
Extent of peritumoral brain edema correlates with prognosis, tumoral growth pattern, HIF1a expression and angiogenic activity in patients with single brain metastases. Clin Exp Metastasis (2012) 0.98
Developmental dyscalculia: compensatory mechanisms in left intraparietal regions in response to nonsymbolic magnitudes. Behav Brain Funct (2009) 0.97
Analysis of aberrant DNA methylation and human papillomavirus DNA in cervicovaginal specimens to detect invasive cervical cancer and its precursors. Clin Cancer Res (2004) 0.96
The risk of carotid artery stenting compared with carotid endarterectomy is greatest in patients treated within 7 days of symptoms. J Vasc Surg (2012) 0.96
The processing and representation of fractions within the brain: an fMRI investigation. Neuroimage (2009) 0.96
Voxel based morphometry reveals specific gray matter changes in primary dystonia. Mov Disord (2007) 0.95
Predictive value of NT-pro BNP after acute myocardial infarction: relation with acute and chronic infarct size and myocardial function. Int J Cardiol (2009) 0.95
Reproducible assessment of radiolucent lines in total knee arthroplasty. Clin Orthop Relat Res (2005) 0.95
CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients. Int J Cancer (2004) 0.95
Anticysticercal and antitoxocaral antibodies in people with epilepsy in rural Tanzania. Trans R Soc Trop Med Hyg (2008) 0.93
Role of biomarkers in assessment of early infarct size after successful p-PCI for STEMI. Clin Res Cardiol (2011) 0.93
Progressive multifocal leukoencephalopathy after allogeneic stem cell transplantation and posttransplantation rituximab. Transplantation (2003) 0.92
Prospective follow-up of patients with acute hepatitis C virus infection in Brazil. Clin Infect Dis (2010) 0.92
Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors. Cancer Sci (2010) 0.92
Detection of low molecular weight derivatives of cyclin E1 is a function of cyclin E1 protein levels in breast cancer. Cancer Res (2006) 0.92
Flexible transfer of knowledge in mental arithmetic--an fMRI study. Neuroimage (2008) 0.92
DNA methylation changes in sera of women in early pregnancy are similar to those in advanced breast cancer patients. Clin Chem (2004) 0.91
Prospective study of the association of serum gamma-glutamyltransferase with cervical intraepithelial neoplasia III and invasive cervical cancer. Cancer Res (2010) 0.91
Differentiation of SCA2 from MSA-C using proton magnetic resonance spectroscopic imaging. J Magn Reson Imaging (2007) 0.91
Topography of dopamine transporter availability in progressive supranuclear palsy: a voxelwise [123I]beta-CIT SPECT analysis. Arch Neurol (2006) 0.91
Do neurooncological patients and their significant others agree on quality of life ratings? Health Qual Life Outcomes (2009) 0.91
DNA ploidy, nuclear size, proliferation index and DNA-hypomethylation in ovarian cancer. Gynecol Oncol (2011) 0.90
Medial temporal lobe activation during semantic language processing: fMRI findings in healthy left- and right-handers. Brain Res Cogn Brain Res (2003) 0.90
Atrophy pattern in SCA2 determined by voxel-based morphometry. Neuroreport (2003) 0.90
Late microvascular obstruction after acute myocardial infarction: relation with cardiac and inflammatory markers. Int J Cardiol (2011) 0.90
Evaluation of striatal dopamine transporter function in rats by in vivo beta-[123I]CIT pinhole SPECT. Neuroimage (2002) 0.90
Intramural duodenal hematoma after upper gastrointestinal endoscopy. Wien Med Wochenschr (2011) 0.89
Comparison of real-time sonoelastography with T2-weighted endorectal magnetic resonance imaging for prostate cancer detection. J Ultrasound Med (2011) 0.89
Comparison of wall thickening and ejection fraction by cardiovascular magnetic resonance and echocardiography in acute myocardial infarction. J Cardiovasc Magn Reson (2009) 0.89
Neural correlates of verbal semantic memory in patients with temporal lobe epilepsy. Epilepsy Res (2006) 0.88
Methylated NEUROD1 promoter is a marker for chemosensitivity in breast cancer. Clin Cancer Res (2008) 0.87
Are numbers special? Comparing the generation of verbal materials from ordered categories (months) to numbers and other categories (animals) in an fMRI study. Hum Brain Mapp (2008) 0.87
RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II study. BMC Cancer (2009) 0.87
Clinical relevance of CDH1 and CDH13 DNA-methylation in serum of cervical cancer patients. Int J Mol Sci (2012) 0.87
The end-of-life phase of high-grade glioma patients: a systematic review. Support Care Cancer (2013) 0.87
Basal forebrain atrophy is a distinctive pattern in dementia with Lewy bodies. Neuroreport (2004) 0.87
Phosphocreatine kinetics in the calf muscle of patients with bilateral symptomatic peripheral arterial disease during exhaustive incremental exercise. Mol Imaging Biol (2007) 0.87
Cortical atrophy in the cerebellar variant of multiple system atrophy: a voxel-based morphometry study. Mov Disord (2006) 0.87
Cardiac imaging using clinical 1.5 t MRI scanners in a murine ischemia/reperfusion model. J Biomed Biotechnol (2010) 0.87
Evaluation of liver fat in the presence of iron with MRI using T2* correction: a clinical approach. Eur Radiol (2013) 0.86
In vivo release of vascular endothelial growth factor from colorectal carcinomas. Oncology (2002) 0.86
Detection and characterization of intracranial aneurysms with MR angiography: comparison of volume-rendering and maximum-intensity-projection algorithms. AJR Am J Roentgenol (2003) 0.86
Differential role of angiogenesis and tumour cell proliferation in brain metastases according to primary tumour type: analysis of 639 cases. Neuropathol Appl Neurobiol (2015) 0.86
E-health approach to link-up actors in the health care system of Austria. Stud Health Technol Inform (2006) 0.86
Isolated numerical skills in posterior cortical atrophy--an fMRI study. Neuropsychologia (2006) 0.85
Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation. J Hepatol (2010) 0.85
Detecting nocturnal hypertension in Parkinson's disease and multiple system atrophy: proposal of a decision-support algorithm. J Neurol (2014) 0.85